Suppliers and packagers for propecia

propecia

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Organon	PROPECIA	finasteride	TABLET;ORAL	020788	NDA	Organon LLC	78206-152-01	30 TABLET, FILM COATED in 1 BOTTLE (78206-152-01)	2021-06-01
Organon	PROPECIA	finasteride	TABLET;ORAL	020788	NDA	Organon LLC	78206-152-02	90 TABLET, FILM COATED in 1 BOTTLE (78206-152-02)	2021-06-01

Suppliers for the Pharmaceutical Drug: Propecia (Finasteride)

Last updated: August 2, 2025

Introduction

Propecia, the brand name for finasteride, is a prescription medication primarily used to treat male-pattern baldness (androgenetic alopecia). Since its FDA approval in 1997, it has become one of the most widely prescribed treatments for hair loss. The drug’s manufacturing, distribution, and supply chain involve a range of entities, from active pharmaceutical ingredient (API) producers to finished drug manufacturers and distributors globally. Understanding the key suppliers across this spectrum is vital for stakeholders aiming to navigate the complex pharmaceutical supply chain, manage costs, or assess supply stability risks.

Manufacturers of Finasteride API

The foundation of Propecia’s production is finasteride’s active ingredient, which is synthesized by multiple chemical and pharmaceutical companies worldwide. The API suppliers play a crucial role, especially given the recent global focus on supply chain resilience and drug security.

1. Molecular Targeting Technology – China's Leading Suppliers

   Chinese pharmaceutical manufacturers, such as Zhejiang Huahai Pharmaceutical and Zhejiang Wanfang Pharmaceutical, are prominent API suppliers for finasteride. Zhejiang Huahai, in particular, has a significant share, leveraging its extensive chemical synthesis capabilities. These players benefit from lower manufacturing costs, making China a dominant source of bulk APIs globally.

2. Indian API Producers

   India-based API producers like Glenmark and Piramal Industries also supply finasteride APIs. Glenmark Pharmaceuticals, with its integrated API and formulation facilities, exports bulk APIs and finished products, supporting both domestic and international markets.

3. European and U.S. API Manufacturers

   While less predominant, several European and U.S. API companies like Mylan (now part of Viatris) and Teva Pharmaceutical Industries participate in the supply of finasteride APIs for regional markets, emphasizing stringent quality controls and regulatory compliance.

Finished Dosage Form Manufacturers

Final Propecia tablets are produced by pharmaceutical companies that either hold licensing agreements with licensed API manufacturers or develop proprietary formulations based on licensed APIs.

1. Merck & Co. (MSD): The Original Innovator

   Merck designed and marketed Propecia, maintaining manufacturing rights for the branded drug. Merck manages the finished product manufacturing through its own facilities, ensuring quality control and regulatory compliance.

2. Generic Manufacturers

   Once patent protections for Propecia expired around 2012, multiple generic pharmaceutical companies began producing finasteride tablets. These companies source APIs from international suppliers or produce API in-house.

   • Sun Pharmaceutical Industries: One of the largest manufacturers of generic finasteride, sourcing APIs globally and producing finished tablets for global markets, including the U.S. and Europe.
   • Cipla: An Indian pharmaceutical firm providing generic finasteride products, utilizing domestically produced APIs and exporting worldwide.
   • Aurobindo Pharma: Active in manufacturing both APIs and finished formulations, supplying generic Propecia equivalents in multiple markets.

Distribution Channels and Supply Chain Dynamics

Beyond manufacturing, the supply chain for Propecia includes distribution wholesalers, pharmacies, and healthcare providers. Major pharmaceutical wholesalers like McKesson and Cardinal Health operate procurement channels that distribute Propecia across the U.S. and international markets. The steady supply depends on reliable API flow, manufacturing capacity, regulatory approvals, and logistical considerations.

Regulatory and Quality Considerations

Suppliers of APIs and finished tablets must meet stringent quality standards outlined by the FDA, EMA, and other regional regulators. Many API producers are registered facilities under Good Manufacturing Practice (GMP) guidelines, ensuring batch consistency and safety. Recent quality concerns, such as those raised about certain Chinese APIs ([1]), have heightened scrutiny and shifted some procurement toward more regulated markets like Europe and North America.

Market Dynamics and Supplier Risks

The global supply landscape for finasteride has experienced fluctuations driven by regulatory changes, geopolitical factors, and supply chain disruptions. Notably:

• China’s role as a primary API source has been challenged by trade tensions and quality control issues, prompting some manufacturers to diversify suppliers.
• Pandemic-induced disruptions caused temporary shortages, emphasizing the importance of diversified sourcing strategies.
• Generic competition has exerted price pressures and encouraged vertical integration among manufacturers.

Emerging Trends in Finasteride Supply Chain

1. Vertical Integration: Larger pharma companies are increasingly investing in in-house API production to mitigate supply risks.

2. Regional Diversification: Sourcing from multiple regions ensures resilience against geopolitical and logistical disruptions.

3. Regulatory Compliance Focus: Ensuring APIs meet high GMP standards is crucial, prompting preference for suppliers with strong regulatory track records.

4. Bioequivalent and Innovative Formulations: Companies are exploring novel delivery formats, which may influence supplier selection and collaborations.

Conclusion

The supply chain for Propecia hinges on a complex network of API producers, finished formulation manufacturers, and distributors across several regions. China remains a dominant API supplier due to cost and capacity advantages, though quality and regulatory concerns are prompting diversification toward Europe and North America. Major generic producers like Sun Pharma, Cipla, and Aurobindo serve significant markets with licensed APIs and formulations. For stakeholders, ensuring supply stability entails vigilant supplier assessment, risk diversification, and compliance with international quality standards.

Key Takeaways

• China dominates finasteride API production, but reliance poses supply risks; diversification is essential.
• Leading generic manufacturers such as Sun Pharma and Cipla operate significant production capacities.
• Regulatory compliance and quality assurance are paramount in API selection and finished product manufacturing.
• Geopolitical factors and supply chain disruptions influence sourcing strategies.
• Vertical integration and regional diversification are emerging trends to enhance supply resilience.

---

FAQs

1. Who are the leading API suppliers for Propecia?
Chinese companies like Zhejiang Huahai Pharmaceutical and Indian firms such as Glenmark are among the main suppliers, with European and U.S. companies also playing roles in regional markets.

2. How has patent expiration affected the supply landscape of finasteride?
Patent expiration around 2012 allowed multiple generic manufacturers to produce finasteride, increasing supply options, lowering prices, and expanding global accessibility.

3. Are there quality concerns associated with Chinese API suppliers?
Yes, certain Chinese API suppliers have faced scrutiny over GMP standards, prompting purchasers to prioritize suppliers with stringent regulatory compliance and seek diversified sourcing.

4. How do regulatory agencies influence supplier choices?
Agencies like the FDA and EMA enforce strict quality standards; suppliers without approved GMP facilities or proper documentation may face restrictions, affecting supply stability.

5. What future trends could impact propecia supply chains?
Vertical integration, regional diversification, and advancements in formulation technology are poised to shape the future of Propecia’s global supply network.

---

References

1. [1] “U.S. FDA warning On Chinese Finasteride APIs,” FDA Regulatory Announcements, 2022.